Bad prognostic factors for response to induction therapy and overall survival in the whole population of 416 patients
| . | Univariate . | Multivariate . | |
|---|---|---|---|
| P value* . | P value* . | HR (95% CI)† . | |
| For induction death | |||
| Advanced age | .008 | .02 | 1.65 (1.08-2.54) |
| High PS | .01 | .003 | 2.81 (1.42-5.56) |
| High WBC | .03 | NS | 1.04 (0.99-1.09) |
| AML type | .06 | NS | 0.34 (0.08-1.49) |
| For CR achievement | |||
| High PS | .02 | NS | 1.47 (0.90-2.40) |
| High-risk karyotype | < .001 | < .001 | 4.11 (2.11-8.03) |
| For overall survival | |||
| Advanced age | .014 | .014 | 1.23 (1.04-1.45) |
| High PS | < .001 | .05 | 1.32 (1.00-1.75) |
| High WBC | .002 | < .001 | 1.04 (1.02-1.07) |
| High-risk karyotype | < .001 | < .001 | 3.95 (2.78-5.61) |
| . | Univariate . | Multivariate . | |
|---|---|---|---|
| P value* . | P value* . | HR (95% CI)† . | |
| For induction death | |||
| Advanced age | .008 | .02 | 1.65 (1.08-2.54) |
| High PS | .01 | .003 | 2.81 (1.42-5.56) |
| High WBC | .03 | NS | 1.04 (0.99-1.09) |
| AML type | .06 | NS | 0.34 (0.08-1.49) |
| For CR achievement | |||
| High PS | .02 | NS | 1.47 (0.90-2.40) |
| High-risk karyotype | < .001 | < .001 | 4.11 (2.11-8.03) |
| For overall survival | |||
| Advanced age | .014 | .014 | 1.23 (1.04-1.45) |
| High PS | < .001 | .05 | 1.32 (1.00-1.75) |
| High WBC | .002 | < .001 | 1.04 (1.02-1.07) |
| High-risk karyotype | < .001 | < .001 | 3.95 (2.78-5.61) |
NS indicates not significant.
P values are given for age as a continuous variable, PS as a 2-class variable (0–1, ≥2), WBC as a continuous variable, AML type (de novo vs post-MDS), and karyotype as a 2-class variable (standard-risk, high-risk).
HRs are given for the high-risk as compared with the standard-risk karyotype subset, for patients with a PS ≥ 2 as compared with those with PS of 0-1, for 10-G/L WBC increment, and for 5-year age increment.